NOVEL DRUG TARGETS FOR CANDIDA ALBICANS

白色念珠菌的新药物靶标

• 批准号: 2070809
• 负责人: JEFFREY M. BECKER
• 金额: $ 28.86万
• 依托单位: UNIVERSITY OF TENNESSEE KNOXVILLE
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-01-01 至 1996-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2070809
• 关键词: Candida albicans; antifungal agents; cooperative study; drug design /synthesis /production; drug screening /evaluation

Individuals infected with HIV are susceptible to a wide range of opportunistic fungal infections. Available drugs to treat the major fungal pathogens are limited due to toxicity and other adverse reactions frequently occurring in people with AIDS. We propose a comprehensive team effort for the discovery of novel drug targets in Candida albicans that is likely to lead to the discovery of agents effective against pathogenic fungi. Three separate but interdependent projects are proposed. Core service units and MycoPharmaceuticals, Inc., a new biotechnology company, will provide reagents and test systems for use by the projects. The Project by Fink will characterize the activities of C. albicans genes controlling dimorphic switching. The elucidation of the dimorphism pathway at the molecular level is likely to reveal targets for development of drugs that will limit the pathogenic potential of this organism. The project by Koltin) will study the mode of action of CaMDR, a C. albican multiple drug resistant protein whose gene was recently cloned in Dr. Koltin's laboratory. Searchers to bypass the resistance mechanism by molecular approaches could identify novel ways to combat disease. The project by Robins will study the molecular biology of chitin biosynthesis in C. albicans. By understanding the relationship between chitin content and pathogenicity, essential cellular targets for drug design will be identified.

感染艾滋病毒的人容易受到广泛的影响 机会性真菌感染。 可用的药物来治疗专业 真菌病原体由于毒性和其他不良反应而受到限制 经常发生在艾滋病的人中。 我们提出了一个全面的 在白色念珠菌中发现新型药物目标的团队努力 这很可能导致发现有效的代理 致病真菌。 三个独立但相互依存的项目是 建议的。 核心服务单位和Mycopharmaceuticals，Inc。 生物技术公司将提供试剂和测试系统，以供 项目。 Fink的项目将表征白色念珠菌基因的活动 控制双态切换。 二态性的阐明 分子水平的途径可能揭示了 开发将限制这一病原潜力的药物 生物。 Koltin的项目将研究CAMDR的作用方式， 白色念珠菌多种耐药蛋白，其基因最近是 克隆在科尔汀博士的实验室中。 搜索者绕过阻力 通过分子方法机制可以确定战斗的新方法 疾病。 罗宾斯的项目将研究 白色念珠菌中的几丁质生物合成。 通过了解关系 在几丁质含量和致病性之间 将确定药物设计。